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Abstract
Excessive matrix metalloproteinase (MMP) activity has been implicated in the pathogenesis of
acute and chronic liver injury. CTS-1027 is a MMP inhibitor, which has previously been studied
in humans as an anti-arthritic agent. Thus, our aim was to assess if CTS-1027 is hepato-protective
and anti-fibrogenic during cholestatic liver injury. C57/BL6 mice were subjected to bile duct
ligation (BDL) for 14 days. Either CTS-1027 or vehicle was administered by gavage. BDL mice
treated with CTS-1027 demonstrated a 3-fold reduction in hepatocyte apoptosis as assessed by the
TUNEL assay or immunohistochemistry for caspase 3/7-positive cells as compared to vehicle
treated BDL animals (p<0.01). A 70% reduction in bile infarcts, a histologic indicator of liver
injury, was also observed in CTS-1027 treated BDL animals. These differences could not be
ascribed to differences in cholestasis as serum total bilirubin concentrations were nearly identical
in the BDL groups of animals. Markers for stellate cell activation (Į-smooth muscle actin) and
hepatic fibrogenesis (collagen 1) were reduced in CTS-1027 versus vehicle-treated BDL animals
(p<0.05). Overall animal survival following 14 days of BDL was also improved in the group
receiving the active drug (p<0.05). In conclusion, in the BDL mouse, liver injury and hepatic
fibrosis are attenuated by treatment with the MMP inhibitor CTS-1027. This drug warrants further
evaluation as an anti-fibrogenic drug in hepatic injury.
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Liver fibrosis and its end stage sequela of cirrhosis represent a major world-wide health
problem. Hepatic fibrosis is the result of an exuberant wound healing response resulting in
excessive collagen deposition in the liver. Hepatic stellate cells are the major source of
collagen in the diseased liver.1 During liver injury, hepatic stellate cells undergo activation
and transdifferentiation to myofibroblasts, which efficiently generate collagen I as part of
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their wound healing response.1 These activated cells, interestingly, also secrete matrix
metalloproteinases which may degrade collagenous and non-collagenous substrates.2
Usually these potent proteases are held in check by the secretion of tissue inhibitors of
metalloproteinases (TIMPS) 1 and 2.2 However, excessive and prolonged MMP secretion
can alter the hepatic scaffolding. This alteration of hepatic architecture results in further
liver injury which in turn elicits increased hepatic damage and fibrosis. It is this upregulated
MMP activity which leads to a feed-forward damage response in liver injury. In particular,
matrix metalloproteinase (MMP) -2, -3 and -9, are upregulated and thought to contribute to
human liver disease.3-5
Inhibition of MMP activity is a potential strategy to minimize liver injury and reduce hepatic
fibrogenesis. For example, inhibition of MMP activity by a MMP inhibitor, BB-94, blocks
hepatocyte apoptosis and improves animal survival in a model of TNF-Į induced acute liver
injury.6 Genetic deletion of MMP13, collagenase-3, attenuates hepatic fibrogenesis in a
cholestatic model of liver injury, the bile duct ligated (BDL) mouse.7 These observations
suggest MMP inhibition may be hepato-protective in liver injury. CTS-1027, N-hydroxy-4-
{[4-(4-chlorophenoxy) benzenesulfonyl] methyl}-2, 3, 5, 6-tetrahydropyran-4-carboxamide,
is a reversible MMP inhibitor. It is an especially potent inhibitor of human MMP 2, 3, 8, 9,
12, 13 and 14 but not 1 or 7. The Ki for inhibiting these MMP is ᚢ9 nM. CTS-1027 appears
to be selective for MMP and has little or no activity for other proteinases including caspases,
the initiator and effector proteinases of apoptosis. This hydroxamate-based inhibitor has
been studied in clinical trials as an anti-arthritic agent. The compound was well tolerated and
side effects were generally mild, reversible and primarily limited to the musculoskeletal
system. Thus, given its safety profile and selectivity in targeting MMP, CTS-1027 is an
attractive agent to inhibit MMP as a potential hepato-protective agent. However, preclinical
studies have not yet been reported addressing a potential hepato-protective effect, although
CTS-1027 is currently in early phase 2 studies in HCV patients.
In this study we assessed the hepato-protective and anti-fibrogenic potential of CTS-1027
during cholestatic liver injury in a preclinical model, the BDL mouse. As compared to
vehicle treated control animals, administration of CTS-1027 attenuates hepatocyte apoptosis,
liver injury and hepatic fibrosis.
MATERIALS AND METHODS
Animal models
The care and use of the animals for the following experiments were reviewed and approved
by the Institutional Animal Care and Use Committee (IACUC) at the Mayo Clinic. C57/BL6
wild-type (wt) mice (6 to 8 weeks of age, 20-25 g of body weight) were employed for these
studies. Mice were maintained in a temperature-controlled (22°C), pathogen-free
environment and fed a standard rodent chow diet and water ad libitum. For experimental
procedures, mice were anesthetized with ketamine 60 mg/kg plus xylazine 10 mg/kg body
weight by intraperitoneal injection. After a midline upper-abdominal incision, the peritoneal
cavity was opened, the abdominal wall retracted, and the common hepatic bile duct was
double-ligated below the bifurcation and transected between the ligatures as previously
described by us in detail.8 Sham-operated mice, used as controls, also underwent similar
laparotomy with exposure but without ligation of the common bile duct. The fascia and skin
of the midline abdominal incision were closed with sterile surgical 5-0 sutures (Ethicon Inc.,
Somerville, New Jersey). Either CTS-1027 (Conatus Pharmaceuticals, San Diego,
California) or the vector carboxymethylcellulose (CMC Sigma-Aldrich, St. Louis, Missouri)
were administered by gavage in a dose of 10 mg/kg body weight once a day. Drugs were
prepared freshly on the day of the study. After 14 days of BDL and gavage, mice were re-
anesthetized, sacrificed and blood was obtained from the inferior vena cava for serum total
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bilirubin and ALT determinations and the liver was removed, cut into small pieces and
either snap-frozen in liquid nitrogen for storage at ᙐ80°C or fixed in freshly prepared 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 48 hours at 4°C for additional
studies (vide infra). Liver tissue was also subjected to RNA extraction using the Trizol
reagent (Invitrogen, Carlsbad, California). Serum bilirubin and ALT determinations were
performed as previously described.9
Histopathology
For histological review of haematoxylin and eosin (H&E)-stained liver sections by light
microscopy (Nikon Eclipse Meta Morph V 5.0.7, West Lafayette, Indiana), the liver was
diced into 5×5 mm sections, fixed in 4% paraformaldehyde for 48 hours and then embedded
in paraffin (Curtin Matheson Scientific Inc., Houston, Texas). Tissue sections (4 ȝm) were
prepared using a microtome (Reichert Scientific Instruments, Buffalo, New York) and
placed on glass slides. H&E staining was performed according to standard techniques.
TUNEL assay and immunofluorescent identification of activated caspases 3/7
Apoptotic cells were quantitated by the terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) assay which enzymatically labels free 3ƍ-OH ends of
damaged DNA with a fluorescently-labeled nucleotide as we have previously described in
detail.10 TUNEL-labeled cells (i.e., fluorescent nuclei) were quantified by counting the
number of positive cells per high-power field. A total of 10 high-power fields were analyzed
for each animal with excitation and emission wavelengths of 490 and 520 nm, respectively,
using an inverted laser scanning confocal microscope (LSM 510, Carl Zeiss Micro-Imaging
Inc., Thornwood, New Jersey) equipped with a 40xNA 1.4 lens and LSM 510 imaging
software. Data were expressed as the number of TUNEL-positive cells/10 high-power fields
(hpf). Immunofluorescence analysis for activated caspases 3/7 was performed using a rabbit
anti-active caspase 3/7 polyclonal antibody (BD Biosciences/Pharmingen, San Diego,
California) recognizing a common neo-epitope shared by activated caspases 3 and 7 as we
have previously described.10 Secondary goat-anti-rabbit antibody conjugated to Texas Red-
X (Invitrogen) was used for visualization of staining. The liver specimens were viewed by
confocal microscopy using excitation and emission wavelengths of 543 and 568 nm,
respectively. The number of caspase 3/7-positive cells was quantified per 10 hpf as
described above for the TUNEL assay. Negative control slides were incubated with non-
immune immunoglobulin under same conditions.
Quantitative Real Time-Polymerase Chain Reaction (qrt-PCR)
Total RNA was isolated from liver tissue using the Trizol reagent (Invitrogen). For each
RNA sample, a 10 ȝg aliquot was reverse-transcribed into complementary DNA (cDNA)
using random primers and Maloney murine leukaemia virus (MMLV) reverse transcriptase
(Invitrogen) as previously described in detail.11 After the reverse transcription reaction, the
cDNA template was amplified by real time PCR with Plantinum Taq DNA polymerase
(Invitrogen) using standard protocols. All amplified PCR products were confirmed by
electrophoresis in 1% low-melting temperature agarose gel, stained with ethidium bromide
and photographed using UV-illumination. The expected base pair PCR products were
identified and the bands cut from the gel. Next, PCR products were eluted into Tris-HCl
using a DNA elution kit (Qiagen, Valencia, California). The concentration of DNA in the
extracted PCR product was measured spectrophotometrically at 260 nm (Beckman DU
4400, Palo Alto, California) and converted to copies/ȝl. Extracted PCR products were
prepared as standards. Quantitative real time PCR was performed using the Light Cycler
(Roche Diagnostics Corp., Mannheim, Germany) and SYBR green as the fluorophore
(Invitrogen) as previously described by us in detail.12, 13 PCR primers (all obtained from the
Mayo DNA Synthesis Core Facility, Rochester, Minnesota) were as follows: Į-SMA
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forward 5ƍ-ACT ACT GCC GAG CGT GAG AT-3ƍ, reverse 5ƍ-AAG GTA GAC AGC GAA
GCC AG-3ƍ (yielding a 452-bp product) and collagen 1Į (I) forward 5ƍ-GAA ACC CGA
GGT ATG CTT GA-3ƍ, reverse 5ƍ-GAC CAG GAG GAC CAG GAA GT-3ƍ (yielding a
276-bp product).
Immunohistochemistry for Į-smooth muscle actin (Į-SMA) and determination of liver
fibrosis by Sirius red staining
The sections were stained for Į-SMA using a mouse monoclonal antibody (Neo Markers,
Fremont, California). The sections were incubated with the primary antibody overnight at 4°
C. Negative control slides were incubated with non-immune immunoglobulin under same
conditions. Secondary reagents were obtained from the Dako Cytomation En Vision +
System-HRP ready-to-use kit (Dako Cytomation Inc., Carpinteria, California) and 3,3ƍ-
diaminobenzidine (DAB) chromogen solution was used for visualization by light
microscopy. Finally, the tissue was counterstained with haematoxylin for 3 minutes. Liver
fibrosis was quantified using Sirius red FSB (also called Direct Red 80) as described.14
Direct red 80 and Fast green FCF (counterstain) were obtained from Sigma-Aldrich
Diagnostics. Liver sections were stained and red-stained collagen fibers were quantified by
digital image analysis as previously described by us in detail.12
Statistical analysis
All data are expressed as the mean ± standard error unless otherwise indicated. Differences
between groups were compared using analysis of variance (ANOVA) for repeated
measurements and post-hoc Bonferroni test to correct for multiple comparisons. A p-value
less than 0.05 was considered to be statistically significant. All statistical analyses were
performed using In-Stat Software (Graph Pad, San Diego, California).
RESULTS AND DISCUSSION
Hepatocyte apoptosis is significantly reduced in the BDL mouse with CTS-1027 treatment
Hepatocyte apoptosis is a prominent feature of cholestatic liver injury and occurs in the bile
duct ligated liver.8 If an agent is to exert hepato-protective properties, it should attenuate
hepatocyte apoptosis. To examine the effects of the MMP inhibitor CTS-1027 on hepatic
apoptosis, mice were subjected to BDL for 14 days. Liver specimens from BDL animals
treated with vehicle demonstrated numerous clusters of apoptotic cells characterized by
condensation of chromatin at the nuclear membrane and fragmentation of the cell into
subcellular bodies in a background of altered hepatic micro-architecture (Fig. 1A). The
MMP inhibitor significantly modified the extent of cell death from numerous clusters of
apoptotic hepatocytes to reduced numbers of isolated apoptotic hepatocytes. Quantitation of
these TUNEL-positive cells demonstrated a 3-fold decrease in BDL mice receiving
CTS-1027 as compared to mice treated with vehicle (Fig. 1A). The activation of executioner
caspases, especially caspases 3 and 7, is a biochemical hallmark of apoptosis.15 Therefore,
to further confirm hepatocyte apoptosis in animals following BDL, we next performed
immunohistochemistry for activated caspases 3/7. Immunoreactive product was readily
identified in liver tissues from mice following BDL, but not in sham-operated controls (Fig.
1B). Consistent with the TUNEL assay, BDL animals receiving CTS-1027 demonstrated a
5-fold decrease in the number of caspase 3/7-positive hepatocytes versus mice treated with
the vehicle (Fig. 1B). Taken together, these data demonstrate that treatment with the MMP
inhibitor CTS-1027 reduces hepatocyte apoptosis in the BDL mouse.
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Features of cholestatic liver injury are significantly reduced in BDL mice treated with
CTS-1027
To further examine the effects of CTS-1027 on liver injury during BDL, histopathological
examination of liver specimens was performed. After 14 days of BDL, mice receiving
vehicle displayed severe cholestatic hepatitis with evidence of widespread bile infarctions
(Fig. 2A) - a pathognomic feature of large bile duct obstruction in this animal.16 This
histopathologic feature of obstructive cholestasis is recognized as confluent regions of
hepatocellular degeneration and was reduced in liver specimens from animals receiving
CTS-1027. Remarkably, these animals displayed almost intact liver morphology with
excellent architectural preservation (Fig. 2A). This difference in cholestatic liver injury
could not be ascribed to alterations in cholestasis as total bilirubin levels were almost
identical in treated and untreated groups of animals (Fig. 2B). Interestingly, after 14 days of
BDL, serum ALT values were not different between the two groups (599±68 vs. 527±89 U/
L, N=8 per group, p>0.05). This observation is consistent with the fact that serum ALT
values are a surrogate marker for liver injury and do not necessarily correlate with tissue
injury as has been observed in human hepatitis C infection.17 Taken together, these
observations suggest MMP inhibition by CTS-1027 is hepato-protective during murine
obstructive cholestasis.
Markers of hepatic fibrogenesis are attenuated in animals following BDL receiving
CTS-1027
If the reduction of liver injury in BDL mice treated with CTS-1027 is significant, it should
also translate into reduced hepatic fibrogenesis - a sequela of liver damage. Because stellate
cells are the principal hepatic cell type responsible for collagen deposition in the liver,18 we
next quantified Į-smooth muscle actin transcripts, markers for stellate cell activation, by
quantitative real time PCR. After 14 days of BDL, mRNA for Į-smooth muscle actin was
reduced 60% in CTS-1027 treated animals as compared to those receiving vehicle (Fig. 3A).
Immunoreactivity for Į-SMA, which was increased in the sinusoid lining cells of BDL mice,
was reduced in BDL mice treated with CTS-1027 (Fig. 3B). To ascertain if stellate cell
activation was also associated with enhanced hepatic fibrogenesis, mRNA for hepatic
collagen 1Į (I) was quantified. Indeed, collagen 1Į (I) mRNA expression was decreased
60% in BDL animals following daily administration of CTS-1027 as compared to mice
receiving the vehicle (Fig. 3C). Hepatic collagen protein deposition was further identified in
liver specimens by Sirius red staining (Fig. 3D) and subjected to computer-assisted
quantitative morphometry for quantification.12 Collagen staining by Sirius red was
decreased approximately 70% treated versus untreated mice in BDL mice (Fig. 3D).
Collectively, these data suggest that in BDL animals, stellate cell activation and hepatic
fibrogenesis are attenuated by administration of the MMP inhibitor CTS-1027.
Overall animal survival following 14 days of BDL is improved in mice receiving the active
drug CTS-1027
Given that liver injury and also hepatic fibrogenesis are significantly reduced in BDL mice
treated with CTS-1027, we reasoned that animal survival should also be enhanced in this
experimental group. Therefore, in our final study, we examined overall animal survival after
BDL following treatment with CTS-1027 versus the CMC vehicle. By day 14 following
BDL, 50% of the animals treated with CTS-1027 were alive as compared to only 20% of the
mice receiving CMC (Fig. 4). Taken together, this study indicates that during obstructive
cholestasis, treatment with the MMP inhibitor CTS-1027 exerts a survival advantage.
In this study we demonstrated that inhibition of matrix metalloproteinases
pharmacologically is beneficial in cholestatic liver injury. Cholestatic liver injury is likely
mediated by a cascade of events. First, the acute retention of toxic bile acids promote
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hepatocyte injury, in part by death receptor-mediated processes.19 This primary hepatocyte
injury elicits a secondary phase of injury characterized by infiltration of inflammatory cells,
activation of Kupffer cells and transformation of quiescent stellate cells to activated
myofibroblasts. A component of the secondary phase of injury is due to matrix
metalloproteinases which induce remodelling of the extracellular matrix. This structural
alteration of the liver further promotes liver injury and enhances hepatocyte apoptosis.
Therefore, it is very likely in our current study that CTS-1027 inhibits the secondary
injurious process in the liver. Interruption of this process attenuates further apoptosis and
hepatic fibrosis. These data are consistent with the ability of matrix metalloproteinase
inhibition to decrease inflammation in tumor necrosis factor-Į/galactosamine treated mice.6
Our study extends these observations by demonstrating an antifibrogenic effect of a MMP
inhibitor in a subacute process of liver injury. There are no data to suggest that these agents
directly enter hepatocytes or alter the primaryphase of bile acid-mediated liver injury.
Consistent with the elevated ALT values observed in both untreated and CTS-1027 treated
BDL animals. Interestingly, in addition to their extracellular localization and function,
MMPs have been demonstrated to be present and functional in the cell nucleus,20, 21
including in the liver.22 Further, they may have a role in apoptosis via their intracellular
activity.20-22 Because CTS-1027 is cell-permeable (unpublished observation), we cannot
exclude a role for intracellular MMP inhibition in the protection of hepatocyes from
apoptosis.
Inhibition of MMP has been amply demonstrated to attenuate acute and chronic liver injury.
6, 7 The current study extends these observations by employing the pharmacologic
compound CTS-1027 in a preclinical model of obstructive cholestasis. This model was
selected because BDL mice consistently undergo hepatocyte apoptosis and hepatic fibrosis
over a subacute time frame, permitting assessment of liver injury and remodeling. In this
model, CTS-1027 was able to attenuate both hepatic injury and liver fibrosis. This model
displays features similar to human liver injury where hepatocyte damage promotes
inflammation, stellate cell activation and hepatic fibrogenesis. However, what is less clear,
is what the effect of CTS-1027 would be in a model where hepatic fibrosis is already
established. One possibility is that CTS-1027 may limit further injury, as in the current
model. Alternatively, because MMP-2, -8 and -13 also degrade collagen,23 broad-spectrum
inhibition of MMP’s could impair the resolution phase of hepatic fibrosis. This concept
could not be explored in the BDL mouse model given the limited survival observed in these
animals. Nonetheless, preventing further fibrogenesis and hepatic injury would have a
salutary effect in human liver disease, even if the previously deposited collagen present in
the matrix could not be degraded. Additional studies using models of chronic fibrosis and
cirrhosis will be necessary to evaluate the effects of CTS-1027 in established fibrotic disease
models. Based on these data, CTS-1027 warrants further study as a hepatoprotective,
antifibrogenic pharmacologic agent in human liver disease. Indeed, a limited clinical trial
with CTS-1027 in hepatitis C patients is currently ongoing.
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Į-SMA Į-smooth muscle actin
BDL bile duct ligation/-ligated
CMC carboxymethylcellulose
ECM extracellular matrix
HSC hepatic stellate cell
MMP matrix metalloproteinase
TIMP tissue inhibitor of metalloproteinase
TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
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Hepatocyte apoptosis is reduced in 14 day BDL treated with CTS-1027. A. The number of
TUNEL-positive cells was quantitated and expressed as apoptotic cells/10 high-power fields
(hpf). Data are from 10 independent animals per group and are expressed as the mean ±
standard error, * p < 0.01 by ANOVA for BDL mice treated with either the MMP inhibitor
CTS-1027 or the vector CMC. B. Immunohistochemistry for the neo-epitopes of caspases
3/7 was performed. Again, data points represent experiments from 10 independent animals
(BDL) or at least 5 sham animals (fewer used because no positive cells were seen in any
sham animal) and bars are expressed as the mean ± standard error, * p < 0.01 by ANOVA
for BDL mice treated with either CTS-1027 or CMC.
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Cholestatic liver injury is attenuated in animals receiving CTS-1027 during BDL. A.
Representative photomicrographs of conventional H & E-stained liver sections
(magnification 20 x) are demonstrated. Liver specimens of BDL mice treated with the vector
CMC displayed significant and extensive hepatocyte injury with bile infarcts (arrows), bile
duct proliferation and portal edema. BDL-induced liver injury was markedly reduced in
animals receiving the active drug CTS-1027, and absent in liver sections of sham-operated
control mice. Bile infarcts (confluent foci of hepatocyte feathery degeneration caused by bile
acid cytotoxicity) were quantified in all experimental groups (n=4 for each condition). B.
Serum total bilirubin determinations are demonstrated 14 days after BDL (n=5 for each
condition).
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Hepatic fibrogenesis is reduced in BDL animals upon treatment with CTS-1027. A. Į-SMA
and collagen 1Į (I) mRNA expression, markers for stellate cell activation and hepatic
fibrogenesis, were quantified by quantitative real time-PCR after 14 days of BDL. Data were
obtained from 10 independent animals and are expressed as the mean ± standard error (* p <
0.05 by ANOVA). B. Photomicrographs after immunohistochemistry for Į-SMA following
14 days of BDL and gavage of either CTS-1027 or the vector CMC are depicted. C.
Expression of collagen 1Į (I) mRNA was quantified by real time-PCR 14 days after BDL
and treatment with either the MMP inhibitor CTS-1027 or the vector CMC (* p < 0.05 by
ANOVA, n = 10 for each group). D. Sirius red staining, a chemical stain of collagen
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deposition in the liver, was performed 14 days after BDL. Collagen fibers stained with
Sirius red were quantitated using digital image analysis. Representative photomicrographs of
liver sections from each experimental condition are depicted (magnification by light
microscopy 40 x). Sirius red staining was quantitatively greater in mice treated with the
vector CMC as compared to mice treated with CTS-1027 following BDL for 14 days (* p <
0.05 by ANOVA, n = 10 for each group).
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Overall animal survival following 14 days of BDL is enhanced in mice upon treatment with
the MMP inhibitor CTS-1027. Initially, on day 7 after bile duct ligation 90 % of animals
treated with CTS-1027 were still alive whereas 100 % of the mice receiving the vector CMC
survived cholestatic liver injury. However, on day 13 after BDL 50 % of animals
administered CTS-1027 by gavage were still alive compared to only 20 % in the group
treated with the vector CMC (n=10 animals per group).
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